Press Releases

Cancer Research's Drug Development Office plans to use the InForm data capture solution to manage up to ten highly specialized trials each year. The organization has pioneered the development of some of the most novel anti-cancer treatments in the marketplace, such as temozolomide, widely recognized as the gold standard treatment for most cases of glioma - the most common form of brain cancer.

In late spring, Cancer Research UK's Drug Development Office initiated a formal evaluation process as part of its Clinical Operations ReEngineering (CORE) project, an initiative that aims to deliver high-quality data faster, with the goal of beating cancer. As part of this initiative, the organization set out to select a best-of-breed electronic data capture (EDC) product, working with multiple vendors to find the ideal business and technical partner to meet the organization's requirements.

After an extensive evaluation, the Drug Development Office selected Phase Forward's InForm solution, based on the partnership approach and flexibility demonstrated by Phase Forward's global services team. Other key factors included technical strength and scalability of the product, the company's broad experience with oncology trials and the availability of investigators trained in using InForm.

"Information is key to our success in managing early stage clinical trials, so it is vital that we invest in the technology to support this important work," said Dr. Nigel Blackburn, director of Cancer Research UK's Drug Development Office. "We were particularly impressed with Phase Forward's commitment to addressing our requirements, as well as the company's experience in developing the data capture tools to manage these trials."

"Cancer Research UK is one of the most respected organizations in the world, advancing the cause of cancer prevention, diagnosis and treatment," said Bob Weiler, chairman and CEO, Phase Forward. "We're honored to work with their dedicated team of professionals to help deliver the next generation of cancer treatments."

The organization's first study using the InForm solution will compare two treatments for metastatic prostate cancer.

About Cancer Research UK's Drug Development Office

Cancer Research UK has an impressive record of developing novel treatments for cancer. It currently has a portfolio of around 40 new anti-cancer agents in preclinical development, Phase I or early Phase II clinical trials. Since 1982, the Cancer Research UK's Drug Development Office has taken over 100 potential new anti-cancer agents into clinical trials in patients, five of which have made it to market and many others are still in development. These include temozolomide, a drug discovered by Cancer Research UK scientists, that is an effective new treatment for brain cancer. Six other drugs are in late development Phase III trials.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7121 6699 or visit www.cancerresearchuk.org.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, demand for Phase Forward's products and services, future business and operations plans of a Phase Forward customer, and the ability of Phase Forward's customers to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, the possibility that customers' needs or plans may change over time, the possibility that the level of demand for Phase Forward's products and services may vary, regulatory changes and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Annual Report on Form 10-K.

Information contained in this release regarding Cancer Research UK and temozolomide has been supplied by Cancer Research UK and Phase Forward Incorporated takes no responsibility for the accuracy or completeness thereof.

SOURCE: Phase Forward

Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com